All these findings together linearize the delicate regulation of AKT kinase by Nedd4l‐CTR1 signaling pathway in a copper‐PDK1 binding dependent manner, and highlight the potential strategy to combat hyperactive AKT‐driven cancers by targeting CTR1‐copper pathway. The gene discussed is NEDD4L; the disease is cancer.